Naproxen Sodium/Sumatriptan Succinate

่˜ๆ™ฎ็”Ÿ้’ /็ฅ็€้…ธ่ˆ’้ฉฌๆ™ฎๅฆ

Report date: 2026/03/04 20:01:44

Base Information

Drug NameNaproxen Sodium/Sumatriptan Succinate
Drug Alias NameSumatriptan Succinate and Naproxen Sodium็ฅ็€้…ธ่ˆ’้ฉฌๆ™ฎๅฆ่˜ๆ™ฎ็”Ÿ้’ Naproxen/Sumatriptan็ฅ็€้…ธ่ˆ’้ฉฌๆ™ฎๅฆ/่˜ๆ™ฎ็”Ÿ้’ ่˜ๆ™ฎ็”Ÿ้’ ็ฅ็€้…ธ่ˆ’้ฉฌๆ™ฎๅฆ +[14]ย 
ClassificationSmall molecules
Mechanisms of ActionSerotonin (5-HT) receptor agonistsCyclooxygenases inhibitors
TargetsSerotonin (5-HT) receptorCyclooxygenases
Therapy Area/IndicationsMigraine without AuraMigraine Disorders
Global Approved IndicationsMigraine Disorders
Approved Indications in ChinaMigraine Disorders
Original Approved Country/TerritoryUnited States
Original Approved Date2008/04/15
Country/TerritoryUnited StatesSouth KoreaMainland China
CombinationsYes NaproxenSumatriptan Succinate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPernix Therapeutics Llc
China Registration ClassN/A

Develop Information

Active CompaniesCurrax Pharmaceuticals LlcSk Chemicals Co LtdJiangsu Kanion Pharmaceutical Co Ltd
Inactive CompaniesGlaxosmithkline PlcPremiere Research InstituteAutobahn Therapeutics Inc +[4]ย 
Active IndicationsMigraine Disorders
Inactive IndicationsMigraine without Aura

Other Information

ATC CodeN02C
Related LinksWikipedia